These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 17460717)

  • 1. Significantly increased lifespan and improved behavioral performances by rAAV gene delivery in adult mucopolysaccharidosis IIIB mice.
    Fu H; Kang L; Jennings JS; Moy SS; Perez A; Dirosario J; McCarty DM; Muenzer J
    Gene Ther; 2007 Jul; 14(14):1065-77. PubMed ID: 17460717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restoration of central nervous system alpha-N-acetylglucosaminidase activity and therapeutic benefits in mucopolysaccharidosis IIIB mice by a single intracisternal recombinant adeno-associated viral type 2 vector delivery.
    Fu H; DiRosario J; Kang L; Muenzer J; McCarty DM
    J Gene Med; 2010 Jul; 12(7):624-33. PubMed ID: 20603889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery.
    Fu H; Dirosario J; Killedar S; Zaraspe K; McCarty DM
    Mol Ther; 2011 Jun; 19(6):1025-33. PubMed ID: 21386820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurological correction of lysosomal storage in a mucopolysaccharidosis IIIB mouse model by adeno-associated virus-mediated gene delivery.
    Fu H; Samulski RJ; McCown TJ; Picornell YJ; Fletcher D; Muenzer J
    Mol Ther; 2002 Jan; 5(1):42-9. PubMed ID: 11786044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Near-Complete Correction of Profound Metabolomic Impairments Corresponding to Functional Benefit in MPS IIIB Mice after IV rAAV9-hNAGLU Gene Delivery.
    Fu H; Meadows AS; Ware T; Mohney RP; McCarty DM
    Mol Ther; 2017 Mar; 25(3):792-802. PubMed ID: 28143737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracranial gene delivery of LV-NAGLU vector corrects neuropathology in murine MPS IIIB.
    Di Domenico C; Villani GR; Di Napoli D; Nusco E; Calì G; Nitsch L; Di Natale P
    Am J Med Genet A; 2009 Jun; 149A(6):1209-18. PubMed ID: 19449420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mannitol-facilitated CNS entry of rAAV2 vector significantly delayed the neurological disease progression in MPS IIIB mice.
    McCarty DM; DiRosario J; Gulaid K; Muenzer J; Fu H
    Gene Ther; 2009 Nov; 16(11):1340-52. PubMed ID: 19587708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved behavior and neuropathology in the mouse model of Sanfilippo type IIIB disease after adeno-associated virus-mediated gene transfer in the striatum.
    Cressant A; Desmaris N; Verot L; Bréjot T; Froissart R; Vanier MT; Maire I; Heard JM
    J Neurosci; 2004 Nov; 24(45):10229-39. PubMed ID: 15537895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical, histological and functional correction of mucopolysaccharidosis type IIIB by intra-cerebrospinal fluid gene therapy.
    Ribera A; Haurigot V; Garcia M; Marcó S; Motas S; Villacampa P; Maggioni L; León X; Molas M; Sánchez V; Muñoz S; Leborgne C; Moll X; Pumarola M; Mingozzi F; Ruberte J; Añor S; Bosch F
    Hum Mol Genet; 2015 Apr; 24(7):2078-95. PubMed ID: 25524704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A GLP-Compliant Toxicology and Biodistribution Study: Systemic Delivery of an rAAV9 Vector for the Treatment of Mucopolysaccharidosis IIIB.
    Meadows AS; Duncan FJ; Camboni M; Waligura K; Montgomery C; Zaraspe K; Naughton BJ; Bremer WG; Shilling C; Walker CM; Bolon B; Flanigan KM; McBride KL; McCarty DM; Fu H
    Hum Gene Ther Clin Dev; 2015 Dec; 26(4):228-42. PubMed ID: 26684447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease correction by combined neonatal intracranial AAV and systemic lentiviral gene therapy in Sanfilippo Syndrome type B mice.
    Heldermon CD; Qin EY; Ohlemiller KK; Herzog ED; Brown JR; Vogler C; Hou W; Orrock JL; Crawford BE; Sands MS
    Gene Ther; 2013 Sep; 20(9):913-21. PubMed ID: 23535899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic efficacy of bone marrow transplant, intracranial AAV-mediated gene therapy, or both in the mouse model of MPS IIIB.
    Heldermon CD; Ohlemiller KK; Herzog ED; Vogler C; Qin E; Wozniak DF; Tan Y; Orrock JL; Sands MS
    Mol Ther; 2010 May; 18(5):873-80. PubMed ID: 20179679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrovirally transduced bone marrow has a therapeutic effect on brain in the mouse model of mucopolysaccharidosis IIIB.
    Zheng Y; Ryazantsev S; Ohmi K; Zhao HZ; Rozengurt N; Kohn DB; Neufeld EF
    Mol Genet Metab; 2004 Aug; 82(4):286-95. PubMed ID: 15308126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease correction in mucopolysaccharidosis type IIIB mice by intraparenchymal or cisternal delivery of a capsid modified AAV8 codon-optimized NAGLU vector.
    Rouse CJ; Hawkins K; Kabbej N; Dalugdug J; Kunta A; Kim MJ; Someya S; Herbst Z; Gelb M; Dinelli I; Butterworth E; Falk DJ; Rosenkrantz E; Elmohd H; Khaledi H; Mowafy S; Ashby F; Heldermon CD
    Hum Mol Genet; 2023 Jan; 32(3):417-430. PubMed ID: 35997776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility and safety of systemic rAAV9-hNAGLU delivery for treating mucopolysaccharidosis IIIB: toxicology, biodistribution, and immunological assessments in primates.
    Murrey DA; Naughton BJ; Duncan FJ; Meadows AS; Ware TA; Campbell KJ; Bremer WG; Walker CM; Goodchild L; Bolon B; La Perle K; Flanigan KM; McBride KL; McCarty DM; Fu H
    Hum Gene Ther Clin Dev; 2014 Jun; 25(2):72-84. PubMed ID: 24720466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucopolysaccharidosis IIIB confers enhanced neonatal intracranial transduction by AAV8 but not by 5, 9 or rh10.
    Gilkes JA; Bloom MD; Heldermon CD
    Gene Ther; 2016 Mar; 23(3):263-71. PubMed ID: 26674264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delivery of an Adeno-Associated Virus Vector into Cerebrospinal Fluid Attenuates Central Nervous System Disease in Mucopolysaccharidosis Type II Mice.
    Hinderer C; Katz N; Louboutin JP; Bell P; Yu H; Nayal M; Kozarsky K; O'Brien WT; Goode T; Wilson JM
    Hum Gene Ther; 2016 Nov; 27(11):906-915. PubMed ID: 27510804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1/2 clinical trial.
    Tardieu M; Zérah M; Gougeon ML; Ausseil J; de Bournonville S; Husson B; Zafeiriou D; Parenti G; Bourget P; Poirier B; Furlan V; Artaud C; Baugnon T; Roujeau T; Crystal RG; Meyer C; Deiva K; Heard JM
    Lancet Neurol; 2017 Sep; 16(9):712-720. PubMed ID: 28713035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell-Mediated Immunity to NAGLU Transgene Following Intracerebral Gene Therapy in Children With Mucopolysaccharidosis Type IIIB Syndrome.
    Gougeon ML; Poirier-Beaudouin B; Ausseil J; Zérah M; Artaud C; Heard JM; Deiva K; Tardieu M
    Front Immunol; 2021; 12():655478. PubMed ID: 34040605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macrophage enzyme and reduced inflammation drive brain correction of mucopolysaccharidosis IIIB by stem cell gene therapy.
    Holley RJ; Ellison SM; Fil D; O'Leary C; McDermott J; Senthivel N; Langford-Smith AWW; Wilkinson FL; D'Souza Z; Parker H; Liao A; Rowlston S; Gleitz HFE; Kan SH; Dickson PI; Bigger BW
    Brain; 2018 Jan; 141(1):99-116. PubMed ID: 29186350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.